Phase 3 Macular Degeneration Trial, Recruiting NCT06990399 Sponsor: Kodiak Sciences Inc Condition: Macular Degeneration
Back to Macular Degeneration

Phase 3 Macular Degeneration Trial, Recruiting

NCT06990399
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have swelling in the central part of your retina (the back of your eye) caused by inflammation, and a scan shows the swelling is above a certain thickness level.
  • A special eye scan shows there is fluid inside or underneath your retina in the eye being studied.
  • Your vision in the eye being studied is reduced but not severely — roughly between 20/40 and 20/320 on a standard eye chart.
  • You have been diagnosed with non-infectious inflammation inside your eye (either currently active or previously treated) in the eye being studied.

Who may not be able to join:

  • The swelling in your retina is caused by diabetic eye disease, a blocked retinal vein, or a certain type of age-related macular degeneration (wet AMD), rather than inflammation.
  • You currently have, or are suspected to have, an active infection in or around either eye.
  • You have a history of, or currently have, a condition where the blood vessels in your retina are inflamed and blocked in either eye (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Pablo Velazquez-Martin, MD, Kodiak Sciences Inc

Phone: (650) 281-0850

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Kodiak Sciences Inc
Registry
ClinicalTrials.gov
Start date
30 July 2025
Est. completion
1 April 2027

Where this trial is recruiting

Puerto Rico 🇺🇸 United States

Primary endpoints

Mean change in BCVA

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov